PMEDAP is a potent inhibitor of human immunodeficiency virus (HIV) replication. PMEDAP has anti-murine cytomegalovirus (MCMV) activity. PMEDAP is a very potent inhibitor of Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality. In Vivo PMEDAP (0.25-5 mg/kg; IP; daily; starting on the day of MSV-infected and continuing for an additional four days) causes a dose-dependent suppression of tumor formation and mortality in newborn mice inoculated with MSV . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Three-week-old male NMRI mice Dosage: 0.25 mg/kg, 1 mg/kg, 5 mg/kg Administration: IP; daily; starting on the day of infection and continuing for an additional four days Result: Effected a significant delay in tumor appearance and an enhancement of the survival rate of tumor-bearing mice. Form:Solid
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
PMEDAP
CAS number：113852-41-8 molecular formula：C8H13N6O4P
overview
compound introduction
Specs
| Chinese alias | 聚乙二醇二甲醚 | ||
| English alias | - | ||
| CAS number | 113852-41-8 | molecular formula | C8H13N6O4P |
| molecular weight | 288.20 g/mol | Exact mass | ≥98% |
| PSA | 162.000 Ų | logp | -2.600 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
